Mostrando 1 - 5 Resultados de 5 Para Buscar '"architect"', tiempo de consulta: 0.12s Limitar resultados
  1. 1
    “…The aim of this study was to compare the performance of the Abbott Panbio(TM) COVID-19 IgG/IgM Rapid Test Device against the Abbott Architect(TM) SARS CoV-2 IgG Assay for the detection of the COVID-19 IgG antibody. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay
  2. 2
    “…Fingerstick plasma collected in Microtainer tubes (n = 109) showed 100% concordant results (R(2)=0.997) with matched patient venous plasma on the ARCHITECT™ SARS-CoV-2 IgG assay. High concordance of assay results (92.9% positive, 100% negative) was also observed for the PANBIO™ SARS-CoV-2 IgG assay compared to the ARCHITECT™ SARS-CoV-2 IgG assay run with matched venous plasma (n = 61). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays
  3. 3
    “…All specimens were screened for HCV using the Abbott RealTime HCV viral load assay and positive specimens with remaining volume were also screened for HPgV‐2 antibodies on the Abbott ARCHITECT instrument, followed by molecular characterization. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort
  4. 4
    “…Newer 4(th)-generation, antigen-antibody combo rapid immunoassay (ARCHITECT) detected HIV in 87 percent of all the acute cases that had been missed by one of the previous screening assays. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Performance of Rapid Point-of-Care and Laboratory Tests for Acute and Established HIV Infection in San Francisco
  5. 5
    por Peluso, Michael J., Takahashi, Saki, Hakim, Jill, Kelly, J. Daniel, Torres, Leonel, Iyer, Nikita S., Turcios, Keirstinne, Janson, Owen, Munter, Sadie E., Thanh, Cassandra, Nixon, Christopher C., Hoh, Rebecca, Tai, Viva, Fehrman, Emily A., Hernandez, Yanel, Spinelli, Matthew A., Gandhi, Monica, Palafox, Mary-Ann, Vallari, Ana, Rodgers, Mary A., Prostko, John, Hackett, John, Trinh, Lan, Wrin, Terri, Petroplolous, Christos J., Chiu, Charles Y., Norris, Philip J., DiGermanio, Clara, Stone, Mars, Busch, Michael P., Elledge, Susanna K., Zhou, Xin X., Wells, James A., Shu, Albert, Kurtz, Theodore W., Pak, John E., Wu, Wesley, Burbelo, Peter D., Cohen, Jeffrey I., Rutishauser, Rachel L., Martin, Jeffrey N., Deeks, Steven G., Henrich, Timothy J., Rodriguez-Barraquer, Isabel, Greenhouse, Bryan
    Publicado 2021
    “…Variations in sensitivity and durability were particularly dramatic for individuals with mild infection, who had consistently lower antibody titers and represent the majority of the infected population, with sensitivities often differing substantially from reported test characteristics (e.g., amongst commercial assays, sensitivity at 6 months ranged from 33% for ARCHITECT IgG to 98% for VITROS Total Ig). Thus, the ability to detect previous infection by SARS-CoV-2 is highly dependent on the severity of the initial infection, timing relative to infection, and the assay used. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
Herramientas de búsqueda: RSS